
ICTS-Supported Facility Accelerates Translation of Promising Research into Improving Outcomes for Cancer and Other Related Diseases
Housed within the Siteman Cancer Center, the Biologic Therapy Core Facility (BTCF) partners with physicians and scientists to manufacture, characterize, and release complex, clinical-grade cell and gene therapy products, imaging agents, and other biologics to support early-phase clinical trials.
The BTCF also supports cellular (e.g. hematopoietic stem cell selections) and tissue therapies (e.g. parathyroid cryopreservation) for Barnes-Jewish Hospital patient care. In addition, the BTCF serves as a source of institutional expertise in current Good Manufacturing Practices (cGMP) to investigators across the institution to ensure strict adherence to phase-appropriate cGMP procedures & regulations in order to provide the highest level of drug or biologic, or cellular product quality for clinical trials…
Read the full article here.



